2001
DOI: 10.1172/jci11015
|View full text |Cite
|
Sign up to set email alerts
|

Tolerance to solid organ transplants through transfer of MHC class II genes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
39
1

Year Published

2002
2002
2015
2015

Publication Types

Select...
4
3
2

Relationship

0
9

Authors

Journals

citations
Cited by 72 publications
(42 citation statements)
references
References 33 publications
2
39
1
Order By: Relevance
“…In rodents, a variety of maneuvers can induce donor-specific allograft tolerance, including pretransplantation priming with donor MHC Ags (blood or splenocytes) (2) (1, 2, 7-10), transfected cells expressing donor MHC Ags (11,12), MHC gene transfer (13,14), or DNA vaccination (15).…”
mentioning
confidence: 99%
“…In rodents, a variety of maneuvers can induce donor-specific allograft tolerance, including pretransplantation priming with donor MHC Ags (blood or splenocytes) (2) (1, 2, 7-10), transfected cells expressing donor MHC Ags (11,12), MHC gene transfer (13,14), or DNA vaccination (15).…”
mentioning
confidence: 99%
“…Experimentally, a variety of maneuvers can induce donor-specific allograft tolerance, including pretransplantation priming with donor MHC Ags (blood or splenocytes) (1-3), transfected cells expressing donor MHC Ags (4), soluble MHC molecules or allopeptides (5), MHC gene transfer (6,7), or DNA vaccination (8). In addition, we have shown that injection of recipients with Abs directed against donor class II MHC can also induce specific tolerance to renal vascularized allografts in adult rats (9,10).…”
mentioning
confidence: 99%
“…These data suggest that unresponsiveness can be achieved in the absence of microchimerism detectable using this PCR assay. Sonntag et al 8 have also reported similar findings following retroviral transfer of MHC class II genes to recipient BM in a renal allograft model in miniature swine. Increasing the dose to 5 × 10 6 CBK BMCs in combination with YTA3.1 pretreatment, enabled us to detect K b mRNA at all time-points up until the time of transplantation in the periphery but less frequently in the thymus (Figure 3a).…”
Section: Discussionmentioning
confidence: 57%
“…3,4 The potential of syngeneic bone marrow cells (BMCs) bearing alloantigen to induce tolerance in animal models has previously been demonstrated in this and other laboratories using transgenic or gene therapy strategies. [4][5][6][7][8] Most gene therapy protocols involving BMCs have employed replication-defective recombinant Moloney murine leukaemia virus (MMLV)-based retroviruses due in part to their ability to stably integrate the transferred genes into the genome of the host cell. The ability of replication-defective, E1-deleted, recombinant adenovirus vectors to transduce whole bone marrow is less well characterised, but these vectors have been shown to be highly effective at transducing many cell types at different developmental stages.…”
Section: Introductionmentioning
confidence: 99%